Specify a stock or a cryptocurrency in the search bar to get a summary
TC BioPharm Holdings PLC
TCBPTC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Address: Maxim 1, Motherwell, United Kingdom, ML1 4WR
Analytics
WallStreet Target Price
140 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures TCBP
Dividend Analytics TCBP
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TCBP
Stock Valuation TCBP
Financials TCBP
Results | 2019 | Dynamics |